Tech Stocks in Motion

Updated from 1:17 p.m.

Shares of TransAct Technologies ( TACT) were among technology's losers Friday, falling 30.2% after the provider of transaction-based printers posted fourth-quarter earnings and sales that were below expectations and warned that first-quarter results would fall short of expectations as well.

Excluding items, the company earned $1.2 million, or 11 cents a share, on sales of $14.6 million. Analysts polled by Thomson First Call were expecting earnings of 13 cents a share on sales of $16.9 million. A year ago, the company earned $1 million, or 9 cents a share, on sales of $14.7 million. The company said that weaker-than-expected gaming and lottery sales hurt fourth-quarter results.

Looking ahead, TransAct forecast first-quarter earnings of 2 cents to 4 cents a share on sales of about $13 million. Analysts had been expecting earnings of 15 cents a share on sales of $17 million. The company said it expects the decline in domestic gaming sales that it experienced in December to continue through the first half of 2005. Shares traded down $5.27 to $12.18.

Credence Systems ( CMOS) fell 9.1% the company posted a first-quarter loss that was wider than expected and warned that second-quarter results would miss expectations. Excluding items, the company -- which makes test equipment used by the semiconductor industry -- posted a loss of $14.9 million, or 17 cents a share, on sales of $93.9 million. Analysts were expecting a loss of 16 cents a share on sales of $102.6 million.

The company said there are signs of improving business conditions, particularly with its IDM customers, but the overall market remains challenging. Looking ahead, Credence forecast a second-quarter loss of 14 cents to 17 cents a share on sales of $94 million to $99 million. Analysts had been expecting a narrower loss of 11 cents a share on sales of $106 million. Shares traded down 83 cents to $8.34.

Shares of Sonus Networks ( SONS) fell 18.3% after the company warned that fourth-quarter sales would fall below expectations. The phone-switch maker expects earnings of 2 cents to 3 cents a share on sales of $43 million to $46 million. Analysts are expecting earnings of 2 cents a share on sales of $49.9 million. Shares traded down $1.01 to $4.50.

Siliconix ( SILI) rose 24.4% after Vishay Intertechnology ( VSH) said it plans to buy the rest of Siliconix that it doesn't already own. Vishay currently owns about 80% of Siliconix's outstanding shares. Late Thursday, Vishay notified Siliconix that it plans to make a tender offer to exchange 2.64 shares of Vishay for each share of Siliconix. Shares of Vishay closed at $13.25 on Thursday, while shares of Siliconix closed at $29.15. Siliconix traded up $7.10 to $36.25, while Vishay traded down 18 cents to $13.07.

Shares of 8x8 ( EGHT) fell 10% after the company said it plans to sell 6.9 million shares of stock at $2.10 apiece, raising about $14.5 million. The sale represents a 12% discount to 8x8's closing price of $2.39. Proceeds from the sale, which is expected to close on Tuesday, will be used to fund working capital and general corporate purposes. Shares traded down 24 cents to $2.15.

Other technology movers included Intel ( INTC), up 18 cents to $24.68; Microsoft ( MSFT), unchanged at $25.17; Sun Microsystems ( SUNW), up 15 cents to $4.36; Oracle ( ORCL), up 19 cents to $13.28; Cisco ( CSCO), up 24 cents to $18.04; Sirius Satellite Radio ( SIRI), down 9 cents to $5.66; and Lucent ( LU), down 3 cents to $3.05.

More from Stocks

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Why Spotify Is the Ultimate Speculative Stock to Buy

Why Spotify Is the Ultimate Speculative Stock to Buy

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data